A systematic review of HbA1c variables used in the study of diabetic complications

Diabetes and Metabolic Syndrome: Clinical Research and Reviews

Volumn 2, Issue 4, 2008, Pages 282-293

  Lind, Marcus ^a   Odén, Anders ^b   Fahlén, Martin ^c   Eliasson, Björn ^d  

^a UDDEVALLA HOSPITAL   (Sweden)

^b CHALMERS UNIVERSITY OF TECHNOLOGY   (Sweden)

^c Kungalv Hospital   (Sweden)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Diabetes mellitus; Diabetic complications; Gradient of risk; HbA1c; HbA1c variable; Predictive power

Indexed keywords

ANTIDIABETIC AGENT; HEMOGLOBIN A1C;

CEREBROVASCULAR ACCIDENT; COMPARATIVE STUDY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DRUG EFFECT; DRUG EFFICACY; FOLLOW UP; HEART INFARCTION; HEMOGLOBIN DETERMINATION; HUMAN; MEDICAL LITERATURE; MICROALBUMINURIA; MICROANGIOPATHY; MORTALITY; OUTCOME ASSESSMENT; PERIPHERAL VASCULAR DISEASE; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; REFERENCE VALUE; REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW; SYSTEMIC DISEASE;

EID: 55649117086     PISSN: 18714021     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dsx.2008.04.006     Document Type: Review

References (104)

1. DCCT Study Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329 14 (September 30) (1993) 977-986
2. DCCT Study Group. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes 44 8 (August) (1995) 968-983
3. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 9131 (September 12) (1998) 837-853
4. Stratton I.M., Adler A.I., Neil H.A., Matthews D.R., Manley S.E., Cull C.A., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321 7258 (August 12) (2000) 405-412
5. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 28 Supplement 1 (January) (2005) S4-S36
6. Selvin E., Marinopoulos S., Berkenblitn G., Rami T., Brancati F.L., Powe N.R., et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 141 6 (September 21) (2004) 421-431
7. Jeffcoate S.L. Diabetes control and complications: the role of glycated haemoglobin, 25 years on. Diabet Med 21 7 (July) (2004) 657-665
8. Lehto S., Ronnemaa T., Pyorala K., and Laakso M. Poor glycaemic control predicts coronary heart disease events in patients with type 1 diabetes without nephropathy. Arteriosclertromb Vasc Biol 19 (1999) 1014-1019
9. Moss S.E., Klein R., Klein B.E., and Meuer S.M. The association of glycemia and cause-specific mortality in a diabetic population. Arch Intern Med 154 21 (November 14) (1994) 2473-2479
10. Laakso M. Glycemic control and the risk for coronary heart disease in patients with non-insulin-dependent diabetes mellitus. The Finnish studies. Ann Intern Med 124 1 Pt 2 (January 1) (1996) 127-130
11. Chen M.S., Kao C.S., Fu C.C., Chen C.J., and Tai T.Y. Incidence and progression of diabetic retinopathy among non-insulin-dependent diabetic subjects: a 4-year follow-up. Int J Epidemiol 24 4 (August) (1995) 787-795
12. Hovind P., Tarnow L., Rossing P., Teerlink T., Stehouwer C.D., Emeis J.J., et al. Progression of diabetic nephropathy: role of plasma homocysteine and plasminogen activator inhibitor-1. Am J Kidney Dis 38 6 (December) (2001) 1376-1380
13. Krishnamurti U., and Steffes M.W. Glycohemoglobin: a primary predictor of the development or reversal of complications of diabetes mellitus. Clin Chem 47 7 (2001) 1157-1165
14. Skyler J.S. Diabetic complications. The importance of glucose control. Endocrinol Metab Clin North Am 25 2 (June) (1996) 243-254
15. WHO. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Technical report series 843. Geneva; 1994.
16. Marshall D., Johnell O., and Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. Br Med J 312 (1996) 1254-1259
17. Araki A., Ito H., Hattori A., Inoue J., Sato T., Shiraki M., et al. Risk factors for development of retinopathy in elderly Japanese patients with diabetes mellitus. Diabetes Care 16 8 (August) (1993) 1184-1186
18. Arun C.S., Pandit R., and Taylor R. Long-term progression of retinopathy after initiation of insulin therapy in type 2 diabetes: an observational study. Diabetologia 47 8 (August) (2004) 1380-1384
19. Zhang L., Krzentowski G., Albert A., and Lefebvre P.J. Risk of developing retinopathy in diabetes control and complications trial type 1 diabetic patients with good or poor metabolic control. Diabetes Care 24 7 (July) (2001) 1275-1279
20. Chaturvedi Microalbuminuria in type 1 diabetes: rates, risk factors and glycaemic, threshold. Kidney Int 60 1 (July) (2001) 219-227
21. Giorgino F., Laviola L., Cavallo Perin P., Solnica B., Fuller J., and Chaturvedi N. Factors associated with progression to macroalbuminuria in microalbuminuric type 1 diabetic patients. Diabetologia 47 6 (June) (2004) 1020-1028
22. Porta M., Sjoelie A.K., Chaturvedi N., Stevens L., Rottiers R., Yeglio M., et al., EURODIAB Prospective Complications Study Group. Risk factors for progression to proliferative diabetic retinopathy in the EURODIAB Prospective Complications Study. Diabetologia 44 12 (December) (2001) 2203-2209
23. Chaturvedi N., Sjoelie A.K., Porta M., Aldington S.J., Fuller J.H., Songini M., et al., EURODIAB Prospective Complications Study. Markers of insulin resistance are strong risk factors for retinopathy incidence in type 1 diabetes. Diabetes Care 24 2 (February) (2001) 284-289
24. Florkowski C.M., Scott R.S., Coope P.A., Graham P.J., and Moir C.L. Age at diagnosis, glycaemic control and the development of retinopathy in a population-based cohort of Type 1 diabetic subjects in Canterbury, New Zealand. Diabetes Res Clin Pract 52 2 (May) (2001) 125-131
25. Florkowski C.M., Scott R.S., Moir C.L., and Graham P.J. Lipid but not glycaemic parameters predict total mortality from type 2 diabetes mellitus in Canterbury, New Zealand. Diabet Med 15 5 (1998) 386-392
26. Gerstein H.C., Pogue J., Mann J.F., Lonn E., Dagenais G.R., McQueen M., et al., HOPE investigators. The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis. Diabetologia 48 9 (September) (2005) 1749-1755
27. Khaw K.T., Wareham N., Luben R., Bingham S., Oakes S., Welch A., et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European prospective investigation of cancer and nutrition (EPIC-Norfolk). BMJ 322 7277 (January 6) (2001) 15-18
28. Kuusisto J., Mykkanen L., Pyorala K., and Laakso M. Non-insulin-dependent diabetes and its metabolic control are important predictors of stroke in elderly subjects. Stroke 25 6 (June) (1994) 1157-1164
29. Lehto S., Ronnemaa T., Pyorala K., and Laakso M. Risk factors predicting lower extremity amputations in patients with NIDDM. Diabetes Care 19 6 (June) (1996) 607-612
30. Lehto S., Ronnemaa T., Pyorala K., and Laakso M. Predictors of stroke in middle-aged patients with non-insulin-dependent diabetes. Stroke 27 1 (January) (1996) 63-68
31. Lehto S., Ronnemaa T., Haffner S.M., Pyorala K., Kallio V., and Laakso M. Dyslipidemia and hyperglycemia predict coronary heart disease events in middle-aged patients with NIDDM. Diabetes 46 8 (August) (1997) 1354-1359
32. Mattock M.B., Barnes D.J., Viberti G., Keen H., Burt D., Hughes J.M., et al. Microalbuminuria and coronary heart disease in NIDDM: an incidence study. Diabetes 47 11 (November) (1998) 1786-1792
33. Mulhauser I., Overmann H., Bender R., Jorgens V., and Berger M. Predictors of mortality and end-stage diabetic complications in patients with Type 1 diabetes mellitus on intensified insulin therapy. Diabet Med 17 10 (October) (2000) 727-734
34. Coonrod B.A., Ellis D., Becker D.J., Bunker C.H., Kelsey S.F., Lloyd C.E., et al. Predictors of microalbuminuria in individuals with IDDM. Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care 16 10 (October) (1993) 1376-1383
35. Lloyd C.E., Klein R., Maser R.E., Kuller L.H., Becker D.J., and Orchard T.J. The progression of retinopathy over 2 years: the Pittsburgh Epidemiology of Diabetes Complications (EDC) Study. J Diabetes Complications 9 3 (July-September) (1995) 140-148
36. Royal College of Physicians of Edinburgh Diabetes Register Group. Near-normal urinary albumin concentrations predict progression to diabetic nephropathy in Type 1 diabetes mellitus. Diabet Med 17 11 (November) (2000) 782-791
37. Leese G. Longitudinal study examining the risk factors for proliferative retinopathy and maculopathy in type-I diabetes: The Royal College of Physicians of Edinburgh Diabetes Register Group. Eye 18 8 (August) (2004) 814-820
38. Standl E., Balletshofer B., Dahl B., Weichenhain B., Stiegler H., Hormann A., et al. Predictors of 10-year macrovascular and overall mortality in patients with NIDDM: the Munich General Practitioner Project. Diabetologia 39 12 (December) (1996) 1540-1545
39. Gaede P., Vedel P., Larsen N., Jensen G.V., Parving H.H., and Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348 5 (January 30) (2003) 383-393
40. van Leiden H.A., Dekker J.M., Moll A.C., Nijpels G., Heine R.J., Bouter L.M., et al. Risk factors for incident retinopathy in a diabetic and nondiabetic population: the Hoorn study. Arch Ophthalmol 121 2 (February) (2003) 245-251
41. Klein R., Klein B.E., and Moss S.E. Relation of glycemic control to diabetic microvascular complications in diabetes mellitus. Ann Intern Med 124 1 Pt 2 (January 1) (1996) 90-96
42. Klein R., Palta M., Allen C., Shen G., Han D.P., and D'Alessio D.J. Incidence of retinopathy and associated risk factors from time of diagnosis of insulin-dependent diabetes. Arch Ophthalmol 115 3 (March) (1997) 351-356
43. Klein R., Klein B.E., Moss S.E., Davis M.D., and DeMets D.L. Glycosylated hemoglobin predicts the incidence and progression of diabetic retinopathy. JAMA 260 19 (November 18) (1988) 2864-2871
44. Klein R., Klein B.E., Moss S.E., and Cruickshanks K.J. Relationship of hyperglycemia to the long-term incidence and progression of diabetic retinopathy. Arch Intern Med 154 19 (October 10) (1994) 2169-2178
45. Klein R., Klein B.E., Moss S.E., and Cruickshanks K.J. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. Ophthalmology 105 10 (October) (1998) 1801-1815
46. Moss S.E., Klein R., and Klein B.E. The 14 year incidence of lower extremity amputations in a diabetic population. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. Diabetes Care 22 6 (June) (1999) 951-959
47. Moss S.E., Klein R., and Klein B.E. The prevalence and incidence of lower extremity amputation in a diabetic population. Arch Intern Med 152 (1992) 610-616
48. Agewall S., Wikstrand J., Ljungman S., and Fagerberg B. Usefulness of microalbuminuria in predicting cardiovascular mortality in treated hypertensive men with and without diabetes mellitus. Risk Factor Intervention Study Group. Am J Cardiol 80 2 (July 15) (1997) 164-169
49. Rossing P., Hougaard P., and Parving H.H. Risk factors for development of incipient and overt diabetic nephropathy in type 1 diabetic patients: a 10-year prospective observational study. Diabetes Care 25 5 (May) (2002) 859-864
50. Cohen J.A., Jeffers B.W., Faldut D., Marcoux M., and Schrier R.W. Risks for sensorimotor peripheral neuropathy and autonomic neuropathy in non-insulin-dependent diabetes mellitus (NIDDM). Muscle Nerve 21 1 (January) (1998) 72-80
51. Gall M.A., Borch-Johnsen K., Hougaard P., Nielsen F.S., and Parving H.H. Albuminuria and poor glycemic control predict mortality in NIDDM. Diabetes 44 11 (November) (1995) 1303-1309
52. The Microalbuminuria Collaborative Study Group. Predictors of the development of microalbuminuria in patients with Type 1 diabetes mellitus: a seven-year prospective study. Diabet Med 16 11 (November) (1999) 918-925
53. Orchard T.J., Olson J.C., Erbey J.R., Williams K., Forrest K.Y., Smithline Kinder L., et al. Insulin resistance-related factors, but not glycemia, predict coronary artery disease in type 1 diabetes: 10-year follow-up data from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care 26 5 (May) (2003) 1374-1379
54. Olson J.C., Erbey J.R., Forrest K.Y., Williams K., Becker D.J., and Orchard T.J. Glycemia (or, in women, estimated glucose disposal rate) predict lower extremity arterial disease events in type 1 diabetes. Metabolism 51 2 (February) (2002) 248-254
55. Watts G.F., Harris R., and Shaw K.M. The determinants of early nephropathy in insulin-dependent diabetes mellitus: a prospective study based on the urinary excretion of albumin. Q J Med 79 288 (April) (1991) 365-378
56. Forrest K.Y., Becker D.J., Kuller L.H., Wolfson S.K., and Orchard T.J. Are predictors of coronary heart disease and lower-extremity arterial disease in type 1 diabetes the same? A prospective study. Atherosclerosis 148 1 (January) (2000) 159-169
57. Lloyd C.E., Kuller L.H., Ellis D., Becker D.J., Wing R.R., and Orchard T.J. Coronary artery disease in IDDM gender differences in risk factors but not risk arteriosclerosis, thrombosis, and vascular biology. Arterioscler Thromb Vasc Biol 16 (1996) 720-726
58. Agardh D.C., Agardh E., and Torffvit O. The association between retinopathy, nephropathy, cardiovascular disease and long-term metabolic control in type 1 diabetes mellitus: a 5 year follow-up study of 442 adult patients in routine care. Diabetes Res Clin Pract 35 2-3 (March) (1997) 113-121
59. Bruno G., Merletti F., Biggeri A., Bargero G., Ferrero S., Pagano G., et al. Progression to overt nephropathy in type 2 diabetes: the Casale Monferrato Study. Diabetes Care 26 7 (July) (2003) 2150-2155
60. Henricsson M., Nystrom L., Blohmé G., Ostman J., Kullberg C., Svensson M., et al. The incidence of retinopathy 10 years after diagnosis in young adult people with diabetes: results from the nationwide population-based Diabetes Incidence Study in Sweden (DISS). Diabetes Care 26 2 (February) (2003) 349-354
61. Nathan D.M., Cleary P.A., Backlund J.Y., Genuth S.M., Lachin J.M., Orchard T.J., et al., Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353 25 (December 22) (2005) 2643-2653
62. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 342 6 (February 10) (2000) 381-389 Erratum in: N Engl J Med 2000 May 4;342(18):1376
63. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA 290 16 (October 22) (2003) 2159-2167
64. White N.H., Cleary P.A., Dahms W., Goldstein D., Malone J., Tamborlane W.V., and Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group. Beneficial effects of intensive therapy of diabetes during adolescence: outcomes after the conclusion of the Diabetes Control and Complications Trial (DCCT). J Pediatr 139 6 (December) (2001) 804-812
65. Henricsson M., Nilsson A., Janzon L., and Groop L. The effect of glycaemic control and the introduction of insulin therapy on retinopathy in non-insulin-dependent diabetes mellitus. Diabet Med 14 2 (February) (1997) 123-131
66. Kalter-Leibovici O., Van Dyk D.J., Leibovici L., Loya N., Erman A., Kremer I., et al. Risk factors for development of diabetic nephropathy and retinopathy in Jewish IDDM patients. Diabetes 40 2 (February) (1991) 204-210
67. Kullberg C.E., and Arnqvist H.J. Elevated long-term glycated haemoglobin precedes proliferative retinopathy and nephropathy in type 1 (insulin-dependent) diabetic patients. Diabetologia 36 10 (October) (1993) 961-965
68. Ohkubo Y., Kishikawa H., Araki E., Miyata T., Isami S., Motoyoshi S., et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 28 2 (May) (1995) 103-117
69. Lovestam-Adrian M., Agardh C.D., Torffvit O., and Agardh E. Diabetic retinopathy, visual acuity, and medical risk indicators: a continuous 10-year follow-up study in Type 1 diabetic patients under routine care. J Diabetes Complications 15 6 (November-December) (2001) 287-294
70. McCance D.R., Hadden D.R., Atkinson A.B., Johnston H., and Kennedy L. The relationship between long-term glycaemic control and diabetic nephropathy. Q J Med 82 297 (January) (1992) 53-61
71. McCance D.R., Hadden D.R., Atkinson A.B., Archer D.B., and Kennedy L. Long-term glycaemic control and diabetic retinopathy. Lancet 2 8667 (October 7) (1989) 824-828
72. Morisaki N., Watanabe S., Kobayashi J., Kanzaki T., Takahashi K., Yokote K., et al. Diabetic control and progression of retinopathy in elderly patients: five-year follow-up study. J Am Geriatr Soc 42 2 (February) (1994) 142-145
73. Olsen B.S., Sjolie A.K., Hougaard P., Johannesen J., Marinelli K., Jacobsen B.B., et al., Danish Study Group pf Diabetes in Childhood. The significance of the prepubertal diabetes duration for the development of retinopathy and nephropathy in patients with type 1 diabetes. J Diabetes Complications 18 3 (May-June) (2004) 160-164
74. Sawicki P.T., Bender R., Berger M., and Muhlhauser I. Non-linear effects of blood pressure and glycosylated haemoglobin on progression of diabetic nephropathy. J Intern Med 247 1 (January) (2000) 131-138
75. Reichard P., and Rosenqvist U. Nephropathy is delayed by intensified insulin treatment in patients with insulin-dependent diabetes mellitus and retinopathy. J Intern Med 226 2 (August) (1989) 81-87
76. Reichard P. Risk factors for progression of microvascular complications in the Stockholm Diabetes Intervention Study (SDIS). Diabetes Res Clin Pract 16 2 (May) (1992) 151-156
77. Reichard P., Pihl M., Rosenqvist U., and Sule J. Complications in IDDM are caused by elevated blood glucose level: the Stockholm Diabetes Intervention Study (SDIS) at 10-year follow up. Diabetologia 39 12 (December) (1996) 1483-1488
78. Reichard P., Nilsson B.Y., and Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 329 5 (July 29) (1993) 304-309
79. Steinke J.M., Sinaiko A.R., Kramer M.S., Suissa S., Chavers B.M., Mauer M., and International Diabetic Nephopathy Study Group. The early natural history of nephropathy in Type 1 Diabetes. III. Predictors of 5-year urinary albumin excretion rate patterns in initially normoalbuminuric patients. Diabetes 54 7 (July) (2005) 2164-2171
80. Tarnow L., Kjeld T., Knudsen E., Major-Pedersen A., and Parving H.H. Lack of synergism between long-term poor glycaemic control and three gene polymorphisms of the renin angiotensin system on risk of developing diabetic nephropathy in type I diabetic patients. Diabetologia 43 6 (June) (2000) 794-799
81. Torffvit O., and Agardh C.D. The impact of metabolic and blood pressure control on incidence and progression of nephropathy. J Diabetes Complications 15 6 (November-December) (2001) 307-313
82. Tung T.H., Chen S.J., Liu J.H., Lee F.L., Li A.F., Shyong M.P., et al. A community-based follow-up study on diabetic retinopathy among type 2 diabetics in Kinmen. Eur J Epidemiol 20 4 (2005) 317-323
83. Twyman S., Rowe D., Mansell P., Schapira D., Betts P., Leatherdale B., and Wessex Diabetic Nephropathy Project. Longitudinal study of urinary albumin excretion in young diabetic patients-Wessex Diabetic Nephropathy Project. Diabet Med 18 5 (May) (2001) 402-408
84. Warram J.H., Scott L.J., Hanna L.S., Wantman M., Cohen S.E., Laffel L.M., et al. Progression of microalbuminuria to proteinuria in type 1 diabetes: nonlinear relationship with hyperglycemia. Diabetes 49 1 (January) (2000) 94-100
85. Yoshida Y., Hagura R., Hara Y., Sugasawa G., and Akanuma Y. Risk factors for the development of diabetic retinopathy in Japanese type 2 diabetic patients. Diabetes Res Clin Pract 51 3 (March) (2001) 195-203
86. Araki S., Haneda M., Sugimoto T., Isono M., Isshiki K., Kashiwagi A., et al. Factors associated with frequent remission of microalbuminuria in patients with type 2 diabetes. Diabetes 54 10 (October) (2005) 2983-2987
87. Nakagami T., Kawahara R., Hori S., and Omori Y. Glycemic control and prevention of retinopathy in Japanese NIDDM patients. A 10-year follow-up study. Diabetes Care 20 4 (April) (1997) 621-622
88. Danne T., Weber B., Hartmann R., Enders I., Burger W., and Hovener G. Long-term glycemic control has a nonlinear association to the frequency of background retinopathy in adolescents with diabetes. Follow-up of the Berlin Retinopathy Study. Diabetes Care 17 12 (December) (1994) 1390-1396
89. DCCT Study Group. Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. Am J Cardiol 75 14 (May 1) (1995) 894-903
90. DCCT Study Group. The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. Diabetes 45 10 (October) (1996) 1289-1298
91. Esmatjes E., De Alvaro F., and 'Estudio Diamante' Investigators Incidence of diabetic nephropathy in Type 1 diabetic patients in Spain: 'Estudio Diamante'. Diabetes Res Clin Pract 57 1 (July) (2002) 35-43
92. Molyneaux L.M., Constantino M.I., McGill M., Zilkens R., and Yue D.K. Better glycaemic control and risk reduction of diabetic complications in Type 2 diabetes: comparison with the DCCT. Diabetes Res Clin Pract 42 2 (November) (1998) 77-83
93. Rossing P., Rossing K., Jacobsen P., and Parving H.H. Unchanged incidence of diabetic nephropathy in IDDM patients. Diabetes 44 7 (July) (1995) 739-743
94. Schultz C.J., Konopelska-Bahu T., Dalton R.N., Carroll T.A., Stratton I., Gale E.A., et al. Microalbuminuria prevalence varies with age, sex, and puberty in children with type 1 diabetes followed from diagnosis in a longitudinal study. Oxford Regional Prospective Study Group. Diabetes Care 22 3 (March) (1999) 495-502
95. Scott L.J., Warram J.H., Hanna L.S., Laffel L.M., Ryan L., and Krolewski A.S. A nonlinear effect of hyperglycemia and current cigarette smoking are major determinants of the onset of microalbuminuria in type 1 diabetes. Diabetes 50 12 (December) (2001) 2842-2849
96. Stratton I.M., Kohner E.M., Aldington S.J., Turner R.C., Holman R.R., Manley S.E., et al. UKPDS 50: risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis. Diabetologia 44 2 (February) (2001) 156-163
97. Adler A.I., Stevens R.J., Neil A., Stratton I.M., Boulton A.J., and Holman R.R. UKPDS 59: hyperglycemia and other potentially modifiable risk factors for peripheral vascular disease in type 2 diabetes. Diabetes Care 25 5 (May) (2002) 894-899
98. Kothari V., Stevens R.J., Adler A.I., Stratton I.M., Manley S.E., Neil H.A., et al. UKPDS 60: risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine. Stroke 33 7 (July) (2002) 1776-1781
99. Stevens R.J., Coleman R.L., Adler A.I., Stratton I.M., Matthews D.R., and Holman R.R. Risk factors for myocardial infarction case fatality and stroke case fatality in type 2 diabetes: UKPDS 66. Diabetes Care 27 1 (January) (2004) 201-207
100. Yokoyama H., Uchigata Y., Otani T., Saeki A., Aoki K., Kasahara T., et al. Metabolic regulation and microangiopathy in a cohort of Japanese IDDM-patients. Diabetes Res Clin Pract 29 3 (September) (1995) 203-209
101. Yokoyama H., Okudaira M., Otani T., Watanabe C., Takaike H., Miuira J., et al. High incidence of diabetic nephropathy in early-onset Japanese NIDDM patients. Risk analysis. Diabetes Care 21 7 (July) (1998) 1080-1085
102. Stevens R.J., Stratton I.M., Holman R.R., and UK Prospective Diabetes Study (UKPDS58). Modeling glucose exposure as a risk factor for photocoagulation in type 2 diabetes. J Diabetes Complications 16 6 (November-December) (2002) 371-376
103. Voutilainen-Kaunisto R.M., Terasvirta M.E., Uusitupa M.I., and Niskanen L.K. Occurrence and predictors of retinopathy and visual acuity in Type 2 diabetic patients and control subjects. 10-year follow-up from the diagnosis. J Diabetes Complications 15 1 (January-February) (2001) 24-33
104. Malmberg K. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. BMJ 314 7093 (May 24) (1997) 1512-1515